// App-Quantinova.ai

POS0525 (2022) : ARE BIOLOGIC AND TARGETED SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ASSOCIATED WITH WORK PARTICIPATION IMPROVEMENT IN EARLY RHEUMATOID ARTHRITIS? A SYSTEMATIC REVIEW AND META-ANALYSIS

Researchers

Presenter

  • M. L. Marques

Principal Investigators

  • A. Alunno

  • L. Falzon

  • A. Boonen

  • S. Ramiro

Medical Centers

  • Leiden University Medical Center (LUMC), Anaesthesiology, Leiden, Netherlands

  • Centro Hospitalar e Universitario de Coimbra, Gastrenterology, Coimbra, Portugal

  • University of L’Aquila, Internal Medicine and Nephrology Unit, MeSVA Department, L’Aquila, Italy

  • The University of Sheffield, Health Economics and Decision Science, School of Health and Related Research, Sheffield, United Kingdom

  • Maastricht University Medical Center, Maastricht, Netherlands

  • Maastricht University Medical Centre and Care and Public Health Research Institute (CAPHRI), Maastricht, Netherlands

Locations

  • Netherlands

  • Portugal

  • Italy

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved